Abstract TH215: A Gut Microbiota-Derived Metabolite Targets Endothelin Signaling to Protect Against Angiotensin II-Induced Hypertension
Hypertension · 2026-10 · 83 (Suppl_1)
DOI: 10.1161/hyp.83.suppl_1.th215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hypertension, 2026-10. Verfasst von Emmanuella Ezewudo und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Angiotensin II (Ang II) is known to contribute to the pathogenesis of hypertension (HTN) through multiple mechanisms, including vasoconstriction, sympathetic activation, cardiovascular remodeling, and renal dysfunction. Emerging evidence indicates that Ang II promotes the generation of reactive oxygen species (ROS), which in turn stimulates the production of endothelin-1 (ET-1). ET-1, the most potent endogenous vasoconstrictor with profound pro-inflammatory effects. In parallel, accumulating evidence suggests that gut microbiota-derived bioactive metabolites play important roles in regulating HTN. In the present study, we investigated the interplay between Ang II-induced HTN and ET-1 production, with a focus on the modulatory effects of indole-3-acetic acid (IAA), a gut microbiota-derived tryptophan metabolite.
Methods
Our in vitro studies were performed using primary mouse mesenteric artery endothelial cells, which were stimulated overnight with Ang II (100 nM) in the presence or absence of IAA (0.01-100 nM), apocynin (100 μM), bosentan (50 μM), aprocitentan (100 nM), or losartan (100 nM). Western blotting and ELISA were used to determine the expression of NADPH oxidase (Nox), endothelin-converting enzyme-1 (ECE-1), and ET-1 production. For in vivo studies, Sprague-Dawley rats received continuous Ang II infusion (700 ng/kg/min) via subcutaneous mini-osmotic pumps for 14 days and were treated by oral gavage with vehicle, extended-release IAA (5, 10, or 20 mg/kg/day), aprocitentan (0.25 mg/kg/day), or losartan (30 mg/kg/day). Blood pressure was monitored daily, 2-4 h after treatment. At the end of the study, vascular function, leukocyte adhesion, urinary albumin excretion, plasma ET-1 levels, and renal fibrosis were evaluated.
Results
Our data demonstrate that Ang II upregulates ECE-1 expression through Nox4-dependent ROS generation, resulting in increased ET-1 production. These effects were attenuated by IAA, as well as by the ROS inhibitor apocynin and the AT1 receptor blocker losartan. In vivo, IAA reduced ET-1 production and attenuated Ang II-induced HTN, while preserving vascular smooth muscle and endothelial function. IAA also decreased leukocyte adhesion, urinary albumin excretion, and renal fibrosis, with protective effects that were comparable to those observed with losartan treatment.
Conclusions
These findings identify the NOX4-ROS-ECE-1-ET-1 pathway as a key mediator of Ang II-induced HTN and provide strong evidence that modulation of ET-1 signaling is an effective strategy for Ang II-dependent HTN. Importantly, our study demonstrates for the first time that the gut microbiota-derived metabolite IAA suppresses ET-1 production and mitigates HTN and organ injury, unveiling a previously unrecognized link between the gut microbiome, Ang II-driven HTN and ET-1 signaling.
Zitieren
APA
Ezewudo, E., Simon, N. P., Oliaie, S. S., Nguyen, T. T., Menon, S., Zerin, F., & Hasan, R. (2026). Abstract TH215: A Gut Microbiota-Derived Metabolite Targets Endothelin Signaling to Protect Against Angiotensin II-Induced Hypertension. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.th215
Vancouver
Ezewudo E, Simon NP, Oliaie SS, Nguyen TT, Menon S, Zerin F, et al. Abstract TH215: A Gut Microbiota-Derived Metabolite Targets Endothelin Signaling to Protect Against Angiotensin II-Induced Hypertension. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.th215
BibTeX
@article{Ezewudo2026,
author = {Ezewudo, Emmanuella and Simon, Nimi Pullenkunnel and Oliaie, Samira Sooreni and Nguyen, Tro Thien and Menon, Sreelakshmi and Zerin, Farzana and Hasan, Raquibul},
title = {Abstract TH215: A Gut Microbiota-Derived Metabolite Targets Endothelin Signaling to Protect Against Angiotensin II-Induced Hypertension},
journal = {Hypertension},
year = {2026},
volume = {83},
number = {Suppl_1},
doi = {10.1161/hyp.83.suppl_1.th215}
}
EUVIMED